Cargando…
Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging
Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) is a heterogeneous and complex group of tumors that are often difficult to classify due to their heterogeneity and varying locations. As standard radiological methods, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486652/ https://www.ncbi.nlm.nih.gov/pubmed/37685279 http://dx.doi.org/10.3390/diagnostics13172741 |
_version_ | 1785103057423433728 |
---|---|
author | Vogele, Daniel Schmidt, Stefan A. Gnutzmann, Daniel Thaiss, Wolfgang M. Ettrich, Thomas J. Kornmann, Marko Beer, Meinrad Juchems, Markus S. |
author_facet | Vogele, Daniel Schmidt, Stefan A. Gnutzmann, Daniel Thaiss, Wolfgang M. Ettrich, Thomas J. Kornmann, Marko Beer, Meinrad Juchems, Markus S. |
author_sort | Vogele, Daniel |
collection | PubMed |
description | Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) is a heterogeneous and complex group of tumors that are often difficult to classify due to their heterogeneity and varying locations. As standard radiological methods, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography–computed tomography (PET/CT) are available for both localization and staging of NEN. Nuclear medical imaging methods with somatostatin analogs are of great importance since radioactively labeled receptor ligands make tumors visible with high sensitivity. CT and MRI have high detection rates for GEP-NEN and have been further improved by developments such as diffusion-weighted imaging. However, nuclear medical imaging methods are superior in detection, especially in gastrointestinal NEN. It is important for radiologists to be familiar with NEN, as it can occur ubiquitously in the abdomen and should be identified as such. Since GEP-NEN is predominantly hypervascularized, a biphasic examination technique is mandatory for contrast-enhanced cross-sectional imaging. PET/CT with somatostatin analogs should be used as the subsequent method. |
format | Online Article Text |
id | pubmed-10486652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104866522023-09-09 Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging Vogele, Daniel Schmidt, Stefan A. Gnutzmann, Daniel Thaiss, Wolfgang M. Ettrich, Thomas J. Kornmann, Marko Beer, Meinrad Juchems, Markus S. Diagnostics (Basel) Review Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) is a heterogeneous and complex group of tumors that are often difficult to classify due to their heterogeneity and varying locations. As standard radiological methods, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography–computed tomography (PET/CT) are available for both localization and staging of NEN. Nuclear medical imaging methods with somatostatin analogs are of great importance since radioactively labeled receptor ligands make tumors visible with high sensitivity. CT and MRI have high detection rates for GEP-NEN and have been further improved by developments such as diffusion-weighted imaging. However, nuclear medical imaging methods are superior in detection, especially in gastrointestinal NEN. It is important for radiologists to be familiar with NEN, as it can occur ubiquitously in the abdomen and should be identified as such. Since GEP-NEN is predominantly hypervascularized, a biphasic examination technique is mandatory for contrast-enhanced cross-sectional imaging. PET/CT with somatostatin analogs should be used as the subsequent method. MDPI 2023-08-23 /pmc/articles/PMC10486652/ /pubmed/37685279 http://dx.doi.org/10.3390/diagnostics13172741 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vogele, Daniel Schmidt, Stefan A. Gnutzmann, Daniel Thaiss, Wolfgang M. Ettrich, Thomas J. Kornmann, Marko Beer, Meinrad Juchems, Markus S. Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging |
title | Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging |
title_full | Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging |
title_fullStr | Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging |
title_full_unstemmed | Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging |
title_short | Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging |
title_sort | gastroenteropancreatic neuroendocrine tumors—current status and advances in diagnostic imaging |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486652/ https://www.ncbi.nlm.nih.gov/pubmed/37685279 http://dx.doi.org/10.3390/diagnostics13172741 |
work_keys_str_mv | AT vogeledaniel gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging AT schmidtstefana gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging AT gnutzmanndaniel gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging AT thaisswolfgangm gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging AT ettrichthomasj gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging AT kornmannmarko gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging AT beermeinrad gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging AT juchemsmarkuss gastroenteropancreaticneuroendocrinetumorscurrentstatusandadvancesindiagnosticimaging |